Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Robinson

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|November 19, 2021
Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing ReformJames C Robinson
Health Services Research|July 19, 2011
Variation in hospital costs, payments, and profitabilty for cardiac valve replacement surgeryJames C Robinson
The Milbank Quarterly|March 8, 2017
Value-Based Physician Payment in Oncology: Public and Private Insurer InitiativesJames C Robinson
JAMA|April 22, 2004
Reinvention of health insurance in the consumer eraJames C Robinson
Health Affairs (Project Hope)|August 21, 2004
For-profit non-conversion and regulatory firestorm at CareFirst BlueCross BlueShieldJames C Robinson
Health Affairs (Project Hope)|December 5, 2022
Germany's Use Of Reference Pricing For Biologics: Lessons For The USJames C Robinson
Health Affairs (Project Hope)|November 15, 2005
Managed consumerism in health careJames C Robinson
JAMA Internal Medicine|July 11, 2017
Medicare Advantage Reimbursement to PhysiciansJames C Robinson
JAMA|August 11, 2025
In (Faint) Praise of Pharmaceutical Import TariffsJames C Robinson
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 4, 2024
<b>Pharmacy Benefit Management:</b> The Cost of Drug Price RebatesJames C Robinson
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|November 19, 2021
Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing ReformJames C Robinson
Health Services Research|July 19, 2011
Variation in hospital costs, payments, and profitabilty for cardiac valve replacement surgeryJames C Robinson
The Milbank Quarterly|March 8, 2017
Value-Based Physician Payment in Oncology: Public and Private Insurer InitiativesJames C Robinson
JAMA|April 22, 2004
Reinvention of health insurance in the consumer eraJames C Robinson
Health Affairs (Project Hope)|August 21, 2004
For-profit non-conversion and regulatory firestorm at CareFirst BlueCross BlueShieldJames C Robinson
Health Affairs (Project Hope)|December 5, 2022
Germany's Use Of Reference Pricing For Biologics: Lessons For The USJames C Robinson
Health Affairs (Project Hope)|November 15, 2005
Managed consumerism in health careJames C Robinson
JAMA Internal Medicine|July 11, 2017
Medicare Advantage Reimbursement to PhysiciansJames C Robinson
JAMA|August 11, 2025
In (Faint) Praise of Pharmaceutical Import TariffsJames C Robinson
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 4, 2024
<b>Pharmacy Benefit Management:</b> The Cost of Drug Price RebatesJames C Robinson
Pageof 10